News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
524,432 Results
Type
Article (38472)
Company Profile (155)
Press Release (485795)
Multimedia
Podcasts (110)
Webinars (16)
Section
Business (150645)
Career Advice (1555)
Deals (29050)
Drug Delivery (122)
Drug Development (70058)
Employer Resources (128)
FDA (12115)
Job Trends (11414)
News (269130)
Policy (29688)
Tag
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1968)
Accelerated approval (30)
Adcomms (28)
Allergies (118)
Alliances (46730)
ALS (131)
Alzheimer's disease (1438)
Antibody-drug conjugate (ADC) (270)
Approvals (12278)
Artificial intelligence (407)
Autoimmune disease (109)
Automation (24)
Bankruptcy (278)
Best Places to Work (8850)
BIOSECURE Act (19)
Biosimilars (174)
Biotechnology (75)
Bladder cancer (117)
Brain cancer (59)
Breast cancer (479)
Cancer (3827)
Cardiovascular disease (316)
Career advice (1329)
Career pathing (26)
CAR-T (199)
CDC (53)
Cell therapy (548)
Cervical cancer (28)
Clinical research (59522)
Collaboration (1560)
Company closure (3)
Compensation (1016)
Complete response letters (62)
COVID-19 (2656)
CRISPR (75)
C-suite (612)
Cystic fibrosis (99)
Data (4771)
Decentralized trials (1)
Denatured (25)
Depression (115)
Diabetes (409)
Diagnostics (4262)
Digital health (26)
Diversity (8)
Diversity, equity & inclusion (36)
Drug discovery (206)
Drug pricing (197)
Drug shortages (34)
Duchenne muscular dystrophy (200)
Earnings (57914)
Editorial (58)
Employer branding (17)
Employer resources (117)
Events (70832)
Executive appointments (707)
FDA (14557)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (17)
Funding (1072)
Gene editing (157)
Generative AI (35)
Gene therapy (508)
GLP-1 (995)
Government (4588)
Grass and pollen (7)
Guidances (322)
Healthcare (12562)
HIV (52)
Huntington's disease (39)
IgA nephropathy (68)
Immunology and inflammation (199)
Immuno-oncology (47)
Indications (86)
Infectious disease (2914)
Inflammatory bowel disease (144)
Inflation Reduction Act (12)
Influenza (110)
Intellectual property (193)
Interviews (269)
IPO (12511)
IRA (51)
Job creations (2911)
Job search strategy (1130)
JPM (52)
Kidney cancer (10)
Labor market (62)
Layoffs (433)
Leadership (24)
Legal (7884)
Liver cancer (73)
Longevity (14)
Lung cancer (532)
Lymphoma (305)
Machine learning (35)
Management (40)
Manufacturing (696)
MASH (148)
Medical device (6682)
Medtech (6711)
Mergers & acquisitions (17468)
Metabolic disorders (1150)
Multiple sclerosis (123)
NASH (21)
Neurodegenerative disease (260)
Neuropsychiatric disorders (80)
Neuroscience (2453)
Neurotech (1)
NextGen: Class of 2026 (4280)
Non-profit (3005)
Now hiring (23)
Obesity (585)
Opinion (269)
Ovarian cancer (117)
Pain (161)
Pancreatic cancer (191)
Parkinson's disease (233)
Partnered (24)
Patents (390)
Patient recruitment (317)
Peanut (45)
People (42153)
Pharmaceutical (71)
Pharmacy benefit managers (26)
Phase 1 (17740)
Phase 2 (25949)
Phase 3 (20682)
Pipeline (4186)
Policy (292)
Postmarket research (2233)
Preclinical (7440)
Press Release (42)
Prostate cancer (185)
Psychedelics (46)
Radiopharmaceuticals (262)
Rare diseases (719)
Real estate (4121)
Recruiting (57)
Regulatory (21115)
Reports (25)
Research institute (1851)
Resumes & cover letters (227)
Rett syndrome (26)
RNA editing (12)
RSV (82)
Schizophrenia (140)
Series A (165)
Series B (119)
Service/supplier (5)
Sickle cell disease (75)
Special edition (16)
Spinal muscular atrophy (158)
Sponsored (30)
Startups (2684)
State (2)
Stomach cancer (16)
Supply chain (95)
Tariffs (93)
The Weekly (83)
Vaccines (1043)
Venture capital (71)
Weight loss (408)
Women's health (57)
Worklife (12)
Date
Today (14)
Last 7 days (431)
Last 30 days (1467)
Last 365 days (22851)
2026 (2108)
2025 (23220)
2024 (26447)
2023 (29742)
2022 (39222)
2021 (42077)
2020 (40254)
2019 (33345)
2018 (25548)
2017 (25253)
2016 (24090)
2015 (27823)
2014 (22008)
2013 (18296)
2012 (19516)
2011 (20307)
2010 (18643)
Location
Africa (708)
Alabama (59)
Alaska (3)
Arizona (164)
Arkansas (7)
Asia (34917)
Australia (5597)
California (7842)
Canada (2561)
China (925)
Colorado (346)
Connecticut (341)
Delaware (272)
Europe (77564)
Florida (1242)
Georgia (238)
Hawaii (4)
Idaho (35)
Illinois (637)
India (61)
Indiana (385)
Iowa (17)
Japan (375)
Kansas (97)
Kentucky (28)
Louisiana (19)
Maine (32)
Maryland (1107)
Massachusetts (5723)
Michigan (183)
Minnesota (325)
Mississippi (2)
Missouri (84)
Montana (24)
Nebraska (13)
Nevada (78)
New Hampshire (34)
New Jersey (2385)
New Mexico (18)
New York (2211)
North Carolina (1076)
North Dakota (5)
Northern California (3828)
Ohio (223)
Oklahoma (10)
Oregon (26)
Pennsylvania (1600)
Puerto Rico (17)
Rhode Island (27)
South America (1008)
South Carolina (35)
South Dakota (1)
Southern California (3090)
Tennessee (98)
Texas (1078)
United States (28288)
Utah (184)
Vermont (1)
Virginia (231)
Washington D.C. (60)
Washington State (622)
West Virginia (3)
Wisconsin (73)
Wyoming (2)
524,432 Results for "santhera pharmaceuticals ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
January 16, 2026
·
4 min read
Press Releases
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
January 8, 2026
·
9 min read
Press Releases
Santhera Closes USD 13 Million Royalty Monetization Agreement
November 5, 2025
·
2 min read
Press Releases
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
January 8, 2026
·
7 min read
Press Releases
Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia
October 9, 2025
·
5 min read
Press Releases
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
October 3, 2025
·
5 min read
Press Releases
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
September 23, 2025
·
6 min read
Press Releases
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
August 13, 2025
·
5 min read
Press Releases
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
August 29, 2025
·
5 min read
Press Releases
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
September 25, 2025
·
2 min read
1 of 52,444
Next
